DV201P-RNA

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

DV201P-RNA is one of 28 biologic programs targeting HIV. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIVRecruiting

HIVPhase 1

Recruiting

Competition

Competitive Landscape

44 competitors in HIV

#DrugCompanyPhaseTrials

Tivicay

GSK

Approved

5 2

Cabenuva

GSK

Approved

2 3

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

6 4

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Epivir

GGlaxo Dba Glaxosmithkline

Phase 3

10 6

Fostemsavir

GSK

Phase 3

1 7

INCMGA00012

Incyte

Phase 3

1 8

Selzentry

GSK

Phase 2

4 9

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 2

2 10

Fosamax

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

HIV

NCT07390474

Clinical

Trials by Indication[1]

HIV1 trial

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07390474·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DV201P-RNA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DV201P-RNA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DV201P-RNA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

DV201P-RNA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

HIV1 trial

References

Drug Info

Quick Facts

Related News